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Cardiac papillary fibroelastomas: A 10-year single-center surgical experience 
and long-term echocardiographic follow-up study
Martin Koleka,b, Jana Dvorackovac, Oldrich Motykad,e, Radim Bratb,f
Aims. Limited contemporary data are available on the clinical and echocardiographic outcomes after surgery for cardiac 
papillary fibroelastoma (CPF). The aim of this study was to review the clinical manifestations, pathological characteris-
tics, surgical management, and prognoses of patients with histologically verified CPF, who underwent surgery at our 
cardiac surgery center from 2008 to 2018.
Methods and Results. Twelve patients of median age 62 years (28 to 77 years) were treated. Embolic stroke or transient 
ischemic attack (five patients, 42%) were the only CPF clinical manifestations. Eleven (92%) tumors were localized on 
the valves, with the aortic valve being the most common tumor site (seven patients; 58%). Multiple factor analysis 
revealed no independent predictor of CPF-related embolization. Simple shave tumor excision was sufficient in most 
patients (10 patients, 83%). No operative or tumor-related late mortality during the median follow-up period of 4.7 
years (1.1 to 10.2 years) was recorded. Asymptomatic metachronous valve tumor recurrence (in a location different 
from that of the original tumor) was revealed in two patients (17%) by transesophageal echocardiography (TEE), not 
detected by transthoracic echocardiography (TTE). One of these two patients underwent repeated surgery for CPF but 
later suffered a recurrent embolic stroke, due to another tumor recurrence.
Conclusion. CPF can be safely and effectively treated surgically. TEE is superior to the TTE option in CPF post-operative 
recurrence detection. There is a clear need for a prospective study to determine criteria for embolization risk stratifica-
tion and optimum management in patients with CPF.
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INTRODUCTION
Primary cardiac tumors are rare, with autopsy stud-
ies reporting incidences between 0.0017% and 0.28%. 
Seventy-five percent of those are benign1,2. The most com-
mon benign cardiac tumor in adults is the cardiac papil-
lary fibroelastoma (CPF) (ref.3,4). As observed by current 
reports using echocardiography for clinical detection of 
the tumor, its occurrence is underestimated in older au-
topsy studies5,6; for example, Tamin et al.4 reported the 
frequency of this tumor at 0.089% of all patients undergo-
ing echocardiography. The histological description is that 
of an avascular papillomatous tumor with a single layer of 
endothelial cells covering the papillary surface7 and con-
taining variable amounts of fine elastic fibrils arranged 
in whorls in a hyaline stroma; surface thrombi may also 
be present. Typically, it affects cardiac valves, especially 
the aortic valve. CPF can be a source of non-fatal or fatal 
thromboembolism or, rarely, interfere mechanically with 
the valvular function. A complete surgical excision of the 
tumor is the most effective curative treatment4,8-11.
Only limited contemporary data are available on CPF 
treatment and outcomes, and studies using transesophageal 
echocardiography (TEE) (ref.4,10) for follow-up are espe-
cially rare. This study retrospectively examines the clini-
cal manifestation, pathology, surgical management, and 
clinical and echocardiographic outcomes of histologically-
verified cardiac papillary fibroelastomas in patients who 
underwent surgery at our tertiary cardiac surgery center. 
MATERIALS AND METHODS
Patients and data collection
The study was approved by The Ethics Committee 
of the University Hospital Ostrava, Czech Republic, ap-
proval No. 821/2017. All patients signed their informed 
consent and agreed with the publication of the results.
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Patients were identified from our cardiovascular sur-
gery and pathology databases. Clinical histories, echocar-
diographic reports, operative notes, and histopathological 
findings were reviewed. Data on symptoms, localization, 
size, and mobility of CPFs were collected, along with 
data on potential CPF-caused valvular defects, types of 
the surgery, complications, and mortality. The principal 
outcomes were tumor recurrence detected by echocar-
diography, the clinical recurrence of embolism, and the 
necessity to re-operate.
During the follow-up, all patients were repeatedly 
examined by transthoracic echocardiography (TTE) 
one week, three months and one year after surgery. 
Subsequent TTEs were performed where the cardiologist 
considered them beneficial. Where the patient agreed, 
TEE was performed in addition to the TTE.
Indications for surgery
Clinical manifestations associated with CPF or asymp-
tomatic mobile tumor were considered primary indica-
tions for CPF surgery (any potential additional cardiac 
pathologies requiring surgical intervention were con-
sidered secondary). Where CPF was found incidentally 
through echocardiography (due to another pathology 
requiring surgical treatment) or perioperatively, it was re-
moved during the combined surgical procedure. Where 
asymptomatic non-mobile CPFs that were not referred 
for a concomitant cardiac surgery were concerned, their 
surgical removal was the preferred method of treatment.
Surgical techniques
A complete valve-preserving excision of the tumor 
(simple shave excision of the root of the pedicle and the 
endocardium involved) was the surgical technique of 
choice. Potential defects caused by an extensive excision 
could be repaired by a direct suture or pericardial patch, 
should the need arise. Where an associated heart valve 
disease required surgery to repair or replace the heart 
valve, it was performed during the same surgery, using 
standard techniques. All patients were operated on by us-
ing median sternotomy and a cardiopulmonary bypass via 
a transaortic approach or via a left or right atriotomy. In 
all patients, intraoperative transesophageal echocardiog-
raphy was performed for assessing the valvular function 
after tumor excision.
Histopathological analysis
Histological examination of the obtained tissue sam-
ples was performed, using basic hematoxylin/eosin stain-
ing as well as the special staining methods acid-Schiff 
(PAS), Alcian blue, Van Gieson, and elastic stain. In some 
cases, immunohistochemical analysis (vimentin, desmin, 
cytokeratin AE1/AE3, CD34, CD31, factor VIII, Ki67, 
S-100, and calretinin) was performed. 
Statistical analysis
Both the statistical analyses of the data and their 
graphical presentation were performed in the R environ-
ment (R Core Team, 2018, R Foundation for Statistical 
Computing, Vienna, Austria) (ref.12). Statistical tests 
were evaluated at a significance level of 5%. Data were 
assessed using basic descriptive statistics, including me-
dian, arithmetic mean, standard deviation, and frequency 
tables with absolute and relative numbers. A factorial 
analysis of mixed data was performed in the R package 
“FactoMineR” (ref.13), and a Kaplan-Meier curve was plot-
ted using the “survival” package14,15. A factorial analysis of 
mixed data allows for the multivariate analysis of datasets 
containing both numeric (quantitative) and categorical 
(qualitative) data. It also helps determine vectors of the 
highest explained variation as well as group the variables 
according to their association.
RESULTS
Patients 
From January 2008 to October 2018, 12 patients with 
CPF were surgically treated at our tertiary cardiac sur-
gery center. Table 1 shows the clinical profile of the study 
group. The average age of the patients was 62 ± 14 years 
(28-77 years), without a statistically significant difference 
between sexes (58% of males).
CPF presence was suspected from echocardiography 
and confirmed histologically after the surgical procedure 
in all patients. Examples of histopathological and echo-
cardiographic results are shown in the Fig. 1.
CPF was a primary reason for the surgery in eight 
patients (67%). The remaining four patients (33%) un-
derwent surgery primarily due to symptomatic valve dis-
ease. Of these four, CPF was diagnosed preoperatively in 
two patients; in the remaining two patients, it was found 
incidentally during surgery. Five patients (42%) had 
a personal history of embolism - a recurrent  transient 
 ischemic attack in two patients (17%), and ischemic stroke 
Table 1. Clinical features of patients.
Variable n=12 (%)
Age (years) 62 ± 14
Male gender 7 (58)
Indication for surgery
 Primary 8 (67)
 Incidental finding 4 (33)
Presentation
 Asymptomatic 7 (58)
 Transient ischemic attack 2 (17)
 Ischemic stroke 3 (25)
 Angina pectoris 0
 Dyspnea 5 (42)
 Palpitations 2 (17)
 Syncope 1 (8)
 Valve dysfunction caused by CPF 0
 Previous cardiac surgery 0
Concurrent cardiac disease
 Coronary artery disease 3 (25)
 Valvular heart disease 6 (50)
 Atrial fibrillation 3 (25)
CPF = cardiac papillary fibroelastoma
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Fig. 1. Papillary fibroelastoma of the mitral valve. (A) Transt-
horacic echocardiography, apical four-chamber view, tumor on 
the anterior mitral leaflet (arrow). (B) Microscopic appearance, 
multiple fronds, hematoxylin/eosin staining, 20x magnification, 
Olympus DP70. LA = left atrium; LV = left ventricle.
in three patients (25%). In the remaining patients, CPF 
was asymp tomatic. None of the patients had angina pec-
toris, and eventual dyspnea, palpitations, or syncope were 
manifestations of coexistent cardiac diseases. CPF did not 
interfere mechanically with the functions of the affected 
valves in any of the patients.
In most patients (11 patients, 92%), CPFs were localiz-
ed on the valves, as shown in Table 2. The aortic valve 
(seven patients; 58%) was the most common tumor site; 
in five of these patients, two or three cusps were affected. 
Altogether, tumorous masses were localized six times on 
the non-coronary cusp, five times on the left, and three 
times on the right coronary cusp (perioperative findings). 
The CPF of the tricuspid valve was localized on its septal 
leaflet.
The location of the tumor with respect to the valve sur-
faces is documented in Table 3. The left ventricular-facing, 
coapting, and aortic-facing surfaces of the noncoronary 
and left coronary aortic cusp were simultaneously in-
volved in one patient. The left ventricular CPF originated 
from the posteromedial papillary muscle. No tumors si-
multaneously affecting multiple valves or heart chambers 
were found.
Table 2. Location of cardiac papillary fibroelastoma.
 
Number of patients 
n=12 (%)
Valve 11 (92)
 Aortic 7 (58)
  One cusp 2
  Two cusps 3
  Three cusps 2
 Mitral 3 (25)
  One leaflet 2
  Two leaflets 1
 Tricuspid 1 (8)
  One leaflet 1
  Two leaflets 0
  Three leaflets 0
Cardiac chamber 1 (8)
 Left ventricle 1 (8)
 Right ventricle 0
 Left atrium 0
 Right atrium 0
 
 
Number of lesions
19
Valve
 Aortic  14
  Noncoronary cusp  6
  Left coronary cusp  5
  Right coronary cusp  3
 Mitral  4
  Anterior leaflet  2
  Posterior leaflet  2
 Tricuspid  1
  Septal leaflet  1
  Anterior leaflet  0
  Posterior leaflet  0
During the multiple factor analysis, no statistically 
significant difference between symptomatic and asymp-
tomatic patients was revealed with respect to the tumor 
location, number of lesions on individual valves, or af-
fected aortic valve surfaces (Fig. 2).
The median diameter of CPF was 5 x 9 mm, ranging 
from 2 x 4 mm to 20 x 20 mm. One-way analysis of vari-
ance revealed that aortic valve tumors were significantly 
smaller than the average (mean diameters 3 x 7 mm vs. 
7 x 9 mm, P=0.03). Furthermore, no difference was de-
tected between asymptomatic patients and those after 
an embolic event (median cross-section diameters 7 x 8 
mm vs. 3 x 9 mm), and therefore no association between 
tumor size and the development of symptoms could be 
confirmed (Fig. 2).
Five fibroelastomas (42%) were mobile spheric or 
egg-shaped pedunculated, five (42%) mobile filiform, 
and two (17%) sessile. Out of the 10 mobile CPFs, five 
were asymptomatic and the remaining five symptomatic; 
both sessile tumors were asymptomatic. The aortic valve 
tumors were significantly more often mobile (P=0.02). 
No association between CPF mobility and embolic risk 
was found (Fig. 2). 
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Histopathology
Very small fragments were formed by avascular 
branching papillary fronds. The stromal tissue was of a 
mixed fibrous/myxoid character, and the papillary sur-
face was covered by a single layer of flattened polygonal 
cells. No polysaccharides were detected in PAS staining. 
In Alcian staining, however, an abundant acidic muco-
polysaccharidic and proteoglycan component was found. 
Van Gieson and elastic staining revealed the organization 
of collagen and elastic fibers, the latter of which were 
sparse in places, even completely missing on the apices 
of the papillae. Avascular fragments were covered with an 
endothelial layer on the surface. These endothelial cells 
expressed factor VIII, CD34, CD31, and S-100 proteins, as 
well as vimentin. Some spindle cells in the deeper layers 
also expressed S-100 protein. Calretinin and desmin, i.e. 
markers used for differential diagnosis with myxoma, were 
negative in the stromal tissue (as typical for CPF), and 
no Ki67 proliferative activity was detected. In both the 
stromal cells and the surface endothelial cells, no AE1/
AE3 cytokeratin activity was found.
Surgery
In most patients (10 patients, 83%), a simple shave tu-
mor excision without the repair of the valve tumor site was 
Table 3. Affected valve surface.
 
n=9
Aortic valve
 left ventricular-facing 2
 coapting 1
 aortic-facing 1
 all 1
Mitral valve
 atrial-facing 3
 coapting 0
 left ventricular-facing 0
Tricuspid valve
 atrial-facing 0
 coapting 1
 right ventricular-facing 0
Fig. 2. Risk factors for embolic events. Factorial analysis of 
mixed data (FAMD), first factor plane. Percentages next to di-
mension names denote the variability explained alongside the 
dimension. Proximity of variables indicates their association.
Table 4. Concomitant procedures.
 n=9
CABG 2
CABG, MVP, TVP 1
MVP 1
MVR 1
MVP, maze 1
MVP, TVP, AVR, maze 1
AVR 1
maze 1
AVR = aortic valve replacement; CABG = coronary artery bypass graft-
ing; MVP = mitral valve plasty; MVR = mitral valve replacement; TVP 
= tricuspid valve plasty; maze = maze procedure (surgical ablation of 
atrial fibrillation)
sufficient. In the remaining two patients, shave excision + 
mitral valve annuloplasty and mitral valve replacement, re-
spectively, were performed; the reason for intervention in 
these two patients was a symptomatic severe mitral regur-
gitation, CPF of the mitral valve was an incidental finding.
Overall, 75% of patients underwent a combined surgi-
cal procedure involving, besides CPF excision, a coronary 
artery bypass grafting (three patients, 25%), a valve repair 
or replacement (six patients, 50%), and a maze procedure 
(two patients, 17%), see Table 4. No patient had a per-
sonal history of previous cardiac surgery.
Clinical and echocardiographic outcome
There was no operative mortality (predicted mortal-
ity according to the EuroSCORE II was 3.6%), see Table 
5. In three patients, however, the following serious post-
operative adverse events were recorded (one in each of 
those patients): Sternal osteomyelitis, cardiac tamponade 
requiring pericardiocentesis, and ventricular fibrillation, 
resolved through successful resuscitation and the subse-
quent secondary preventive implantation of a cardioverter-
defibrillator.
The clinical follow-up period ranged from 1.1 to 10.2 
years, with a median of 4.7 years. The one-year survival 
rate was 100%, and the survival rate during the median 
follow-up time was 92%, see Table 5. Three patients died 
over the course of the follow-up, as exemplified in Fig. 3 
with a Kaplan-Meier survival curve. Causes of death in-
cluded pleuropneumonia, generalization of a malign tes-
ticular lymphoma, and intracerebral bleeding in a patient 
with a generalized stomach adenocarcinoma. There was 
no late mortality related to CPF.
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Four months after surgery, an embolic stroke occurred 
in one patient with a mechanical mitral valve (surgery 
performed primarily due to a severe mitral regurgitation, 
mitral valve CPF was an incidental finding). The embo-
lization occurred at a subtherapeutic international nor-
malized ratio value, without any clear dysfunction of the 
mechanical prosthesis or CPF recurrence. Following an 
interventional therapy, no residual neurological deficit 
was observed. Over the following months, the patient’s 
condition was two times more complicated by a throm-
bosis of the mitral valve prosthesis. The first one was 
treated through systemic thrombolysis, during which an 
embolism in the brain and right kidney occurred. At the 
second thrombosis of the valve prosthesis, the patient 
underwent another operation, and the mechanical mitral 
valve prosthesis was replaced with a bioprosthesis.
Repeated transthoracic echocardiography was per-
formed in all patients during the follow-up. The median 
TTE follow-up time was 4.2 years (0.6 to 9.8 years), and 
no evidence of any tumor recurrence was found.
In seven patients (58%), a follow-up TEE was per-
formed as well. The median TEE follow-up time was 1.7 
years (0.6 to 5.8 years), and no recurrences of cardiac 
papillary fibroelastoma were observed in five patients (42% 
of the entire group), see Table 5. In the remaining two 
patients (17%) with a follow-up TEE, however, tumor re-
currence in a location different from the original one was 
detected. The first of these two patients originally under-
went surgery because of a fibroelastoma originating from 
the posteromedial papillary muscle of the mitral valve. Six 
years after the surgery, TEE revealed a 6 mm-long suspect-
ed asymptomatic mobile filiform CPF of the non-coronary 
and right coronary aortic cusps. Due to a relatively high 
operative risk, the patient did not accept the re-operation 
and preferred permanent warfarin anticoagulant treatment. 
The other patient with complications originally under-
went a primary excision of an aortic valve CPF. One year 
later, TEE revealed a 6 mm-long metachronous asymp-
tomatic mobile filiform CPF of the anterior leaflet of the 
mitral valve. Repeated surgery—an isolated simple shave 
excision—was performed with no peri- or postoperative 
complications. The CPF diagnosis was confirmed histo-
pathologically. A follow-up TEE performed 3.5 months 
later, however, again detected a newly suspected metachro-
nous asymptomatic mobile filiform tumor of 5-10 mm on 
both the aortic and the mitral valves (identical morphol-
ogy as in the previous detection). Due to the patient’s 
general non-compliance, a decision to treat the patient 
conservatively with an antiplatelet drug was made; the 
patient, however, avoided taking the medication. In this 
patient, the only symptomatic embolic event occurring 
solely in connection with a CPF diagnosis, namely a re-
current ischemic stroke with a mild residual focal neuro-
logic deficit, was recorded 4.5 months after the second 
surgery, as shown in Table 5. The recommendation to use 
anti-aggregation therapy was repeated.
Retrospectively, records of all pre-operative TEE ex-
aminations of these two patients were re-examined. No 
evidence was found of CPF presence in the locations 
where metachronous CPF recurrences had developed. 
Table 5. Outcome.
 n=12 (%)
Mortality/survival  
 Operative mortality 0
 One-year survival 12 (100)
 Survival in median follow-up time 11 (92)
Tumor recurrence  
 Clinically 1 (8)
 TTE recurrence 0
 TEE recurrence 2 (17)†
Intervention due to recurrence  
 Re-operation 1 (8)‡
 Anticoagulation (warfarin) 1 (8)
TEE = transesophageal echocardiography; TTE = transthoracic echo-
cardiography
† metachronous tumors – other than the originally affected site
‡ another recurrence of the tumor on both previously affected valves 
after re-operation, then no surgical/antithrombotic therapy (non-com-
pliance)
Fig. 3. Kaplan-Meier survival estimate – overall cumulative 
survival of the entire cohort (the longest follow-up period is 
terminated by patient’s death, hence the drop to 0).
Moreover, no abnormalities were apparent on TTE ex-
aminations performed between the surgeries and the TEE 
detection of recurrent tumors, either.
DISCUSSION
History
Papillary fibroelastoma was first characterized histo-
logically, histochemically, and by electron microscopy in 
1975 by Fishbein et al.16. In 1979, Lichtenstein was the 
first to describe a large incidentally found CPF, resected 
during the surgical closure of an interventricular septal 
defect in an adult17. The first pre-operative echocardio-
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graphic CPF diagnosis was made by Flotte et al. in 1980 
(ref.18).
Epidemiology
CPF can occur at any age, but it is nonetheless the 
most common in the fourth to eighth decades of life. The 
mean age of detection is approx. 60 years4,5,8-10, and in 
most studies, it has a greater affinity to the male sex8-10. 
In our patient group, age and sex patterns are consistent 
with previous studies. 
CPFs are either neoplastic processes, hamartomatous 
lesions, or reactive growths. The CPF etiology remains 
unknown and no clear risk factor association for the de-
velopment of this tumor has been discovered to date9. 
The natural history of CPFs has not been defined herein, 
because no long-term longitudinal follow-up studies utiliz-
ing echocardiography have been performed. 
Pathology
According to the comprehensive analysis of 725 cases 
of CPF, published by Gowda et al.8, the valvular surface 
was the predominant location of the tumor (84%). The 
aortic valve was the most commonly involved (44%), fol-
lowed by the mitral valve (35%). The left ventricle was the 
predominant non-valvular site of tumor origin. Multiple 
tumors on a single or multiple location were diagnosed 
in 39 patients from the abovementioned patient group. 
Tumor size ranged from 2 to 70 mm, typically around 10 
mm in their greatest dimension.
The pathological-anatomical characteristics of our 
patient group are similar to those reported in other stud-
ies4,9,10. In the study by Tamin et al.4, CPFs in patients 
presenting with a neurological event resulting from CPF 
were significantly smaller than CPFs in those who pre-
sented with other indications. Most tumors in our patient 
group were mobile (84%), which is almost twice as many 
as in the study by Sun et al.5, who only reported 44% 
of mobile CPFs. There is no agreement among studies 
on the involved valvular surfaces: While Sun et al.5 re-
ported that most tumors presented on the aortic side of 
the valve, Ngaage et al.9 found most tumorous masses on 
the ventricular surfaces of aortic cusps and mitral leaflets, 
and in the study by Tamin et al.4, an approximately equal 
proportion of CPFs arose from the aortic and ventricu-
lar surfaces of the aortic valve. Our results, as far as the 
aortic valve is concerned, are in agreement with this last 
mentioned study.
Tumor size/volume, the site of left heart tumors, and 
the valvular surface involved are not determinants of sys-
temic thromboembolism4,8-10. According to Gowda et al.8, 
the only independent predictor of CPF-related death or 
nonfatal embolization was tumor mobility. In contrast, 
in the study by Tamin et al.4, mobility was not signifi-
cantly associated with an occurrence of cerebrovascular 
accidents, possibly due to a smaller group size. In our 
relatively small patient group, there was no difference in 
the pathological-anatomical characteristics of CPFs as-
sociated or disassociated with embolism.
Clinical diagnostics
CPF is increasingly diagnosed clinically, i.e. ante-mor-
tem. The rate of underdiagnosis, however, is still relatively 
high, because CPFs are often asymptomatic3. They are 
often diagnosed incidentally at the time of echocardiog-
raphy, computed tomography, cardiac surgery, or autopsy. 
There is a wide range of possible clinical manifestations of 
left heart CPFs, the most common of which is an embolic 
transient ischemic attack or stroke, especially in patients 
with mitral valve tumors. Aortic valve tumors are more 
commonly manifested by sudden death or myocardial 
infarction8,9. In our study, embolic neurological events 
were the only manifestation in patients undergoing sur-
gery primarily for this tumor. Right heart CPF can also 
manifest through a paradoxical systemic embolism in the 
presence of a patent foramen ovale9,19. Rarely, CPF may 
cause a valve stenosis or regurgitation, due to an interfer-
ence with the valve closure. None of these occurred in 
our patient group.
The imaging method of choice for CPF detection is 
echocardiography, with TEE allowing a more accurate 
assessment than TTE. In the study by Tamin et al.4, both 
TTE and TEE revealed the tumor in 51% of patients, while 
in 33% of patients, the tumor could be detected only by 
TEE. A small, mobile, pedunculated or sessile valvular, 
or endocardial masses, fluttering or prolapsing into the 
cardiac chambers during systole or diastole, are observed. 
There are, however, no specific echocardiographic fea-
tures allowing a definite diagnosis of CPF. Fibroelastoma 
should be generally considered if a mobile echogenic 
structure with a speckled appearance, echolucencies, 
and a stippled pattern near the edges is detected6. Three-
dimensional echocardiography has an incremental value 
over two-dimensional echocardiography in the assessment 
of these tumors, since it allows for acquiring true CPF 
dimensions and offers additional real-time information on 
its shape, mobility and relationship to other structures20-22. 
In all of our patients, the presence of CPF was suspected 
solely on the basis of two-dimensional TEE, and no other 
imaging methods were used.
Treatment
The treatment of choice for both symptomatic and 
asymptomatic mobile CPF is a surgical excision includ-
ing the full thickness of the endocardium involved. A 
potential resulting defect is either sutured directly or a 
pericardial patch closure is performed. A complete surgi-
cal excision has a curative effect with a high probability 
of preserving the affected valve4,8,23. Where the valve is 
gravely damaged, its repair or replacement are necessary. 
In the often quoted study of Gowda et al.8, a surgical 
CPF excision was carried out in 425 patients, of which 
the valve repair was required in 9% and a valve replace-
ment in 10%. In a study by Ngaage et al.9, comprising 88 
patients, CPF was a primary indication for surgery in 53% 
of patients and an incidental finding in 47% of patients. 
Shave excision was sufficient in most patients (83%), 
eight patients (9%) underwent an excision with a valve 
repair and five (6%) had valve replacements. Of these five 
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valve replacements, two were due to a concurrent degen-
erative valve disease. Concomitant procedures included 
the repair or replacement of another valve (32%), coro-
nary artery bypass grafting (28%), and septal myectomy 
(19%). In the study by Tamin et al.4, histopathologically 
confirmed CPF was surgically removed in 185 patients; 
in 94 patients (51%), CPF was the primary reason for the 
surgery, while in 91 patients (49%), the surgery was due 
to another problem. In valvular CPFs removed during 
primary surgery, the valve was preserved in 92 patients 
(98%). In our patient group, CPF excision was combined 
with another intervention in a majority of patients. A sim-
ple shave tumor excision with preservation of the valve, 
as in the abovementioned studies, was sufficient in most 
patients.
Out of 25 patients in the study by Gowda et al.8 who 
did not undergo surgical excision of CPF, 12 patients suc-
cumbed to a CPF-related death and four patients suffered 
a nonfatal embolization. Hence, the authors concluded 
that symptomatic patients who, for any reasons, do not 
undergo surgery should be treated with long-term oral 
anticoagulation; it is, however, necessary to point out here 
that its efficacy has not been confirmed in any random-
ized controlled study.
The study by Tamin et al.4 includes a relatively large 
group of 326 patients in whom CPF was echocardiograph-
ically suspected but no surgical removal was performed. 
In these patients, rates of cerebrovascular accident and 
mortality were increased. The risk of stroke in unoperated 
CPF was 6% and 13% at one and five years, respectively 
(which was higher than age- and sex-matched rates), while 
in patients in whom surgery was performed primarily due 
to CPF, the reported risks were 0% and 5% at one and five 
years, respectively. There was no significant difference 
in the occurrence of subsequent stroke between patients 
treated with warfarin or antiplatelet drugs versus those not 
taking medication. The authors nevertheless concluded 
that the study may not have the statistical power to evalu-
ate the benefit of antithrombotic therapy.
The management of asymptomatic non-mobile lesions 
is a controversial topic23. An excision of asymptomatic 
CPF is recommended in patients requiring concomitant 
cardiac surgery, as it can be achieved with acceptable re-
sults4. No data, however, are available on the management 
and therapy of patients with asympto matic non-mobile 
CPF who have not been referred for concomitant car-
diac surgery. According to Gowda et al.8, these patients 
should be followed up clinically and echocardiographi-
cally, since the development of symptoms or the tumor 
turning mobile is an indication for surgery. No consistent 
and validated method for the embolism risk prediction is 
available, though, and so for this reason, other authors 
recommend an aggressive surgical approach, i.e. perform-
ing the surgical removal of CPF in all patients with an 
acceptable surgical risk4,9,24. We believe that it is neces-
sary to perform a randomized trial aimed at developing 
criteria for risk stratification and preparing guidelines for 
the management of patients with asymptomatic CPF. Due 
to the rarity of this disease, however, such a trial would 
have to be multicentric.
Outcome
All published studies agree on zero11,25,26 or very low 
(approx. 1%) (ref.4,9) in-hospital/30-day mortality in pa-
tients undergoing CPF excision. 
The long-term prognosis following a surgery for CPF 
is good as well. No recurrence of the tumor was reported 
in most (predominantly older) studies5,8,9,11. More recently 
published papers4,10 report very low recurrence rates. This 
increased capture of (predominantly asymptomatic) recur-
rences in more recent studies is probably associated with 
an increased use of echocardiography during the follow-
up. New CPFs may arise at or near the site of a previous 
resection, due to an endocardial injury; an incomplete 
resection can be another possible cause of the recurrence.
Anastacio et al.10 published their experiences of sur-
gery for CPF in 23 patients (with 29 lesions). After a 
tumor excision, the mean follow-up was 37 months (range, 
one month - 10 years). In 18 patients, a postoperative TTE 
was performed, and in one patient, TEE was performed. 
A metachronous lesion on the aortic valve was detected 
in one patient three months after the initial surgical in-
tervention (which was performed primarily due to a le-
sion on the pulmonary valve and another lesion in the 
right atrium); the diagnosis was histologically confirmed. 
Echocardiography was carried out in 66% of patients at a 
median of 2.9 years (IQR: 0.9 to 5.3 years) in the already 
cited paper by Tamin et al.4, in which the post-operative 
recurrence of CPF was 1.6% (three out of 185 patients). 
In our group, an asymptomatic metachronous tumor re-
currence was revealed in two patients (17%) by TEE, while 
TTE did not reveal any recurrence. In both patients, the 
tumor developed in a different location than the primary 
occurrence. In one of these patients, re-operation was suc-
cessfully performed; however, new asymptomatic recur-
rences were detected by TEE on both previously affected 
valves. As expected, TEE is significantly more sensitive 
than TTE where the detection of recurrent CPFs is con-
cerned. A standard practice of using TEE for follow-up 
in patients after CPF excision—in our opinion—therefore 
deserves a thorough discussion.
No tumor-related late morbidity or mortality during 
the follow-up was reported by Sun5 or Ngaage9. Ten cere-
brovascular accidents (in a group of 185 patients – after 
both primary or concomitant surgery) were recorded 
during follow-up by Tamin et al.4, with the overall risk of 
stroke at 2% and 8% at one and five years, respectively. 
In our study group, one embolic stroke associated with 
CPF recurrence was registered in the abovementioned 
non-compliant patient.
CONCLUSION
We present a single cardiac surgery center experience 
with the surgical treatment of CPF in a small group of 
patients, including long-term follow-up using echocardiog-
raphy. No independent predictor of CPF-related nonfatal 
embolization was identified when using multiple factor 
analysis. CPF can be safely and effectively treated surgi-
cally, and for our patients, a simple shave tumor excision 
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was sufficient in almost all cases. There was no operative 
mortality and no tumor-related late mortality during the 
long-term clinical follow-up. Transesophageal echocar-
diography was superior to transthoracic echocardiography 
in the detection of asymptomatic metachronous tumor 
recurrence in two patients (in a location different from 
that of the original tumor). One of these two patients 
underwent repeated surgery for CPF but later suffered 
a recurrent embolic stroke, caused by newly recurrent 
metachronous tumors. The retrospective design and small 
number of patients were the most significant limitations 
of this study.
There is a clear need for a prospective study or stud-
ies aiming at determining criteria for embolization risk 
stratification as well as optimum management strategies, 
in particular in patients with an asymptomatic non-mobile 
CPF. Based on the data currently available, surgical exci-
sion should be considered in patients with a low surgical 
risk and left-sided CPF regardless of tumor size, mobil-
ity, or location. Such an aggressive surgical approach is 
supported by a high likelihood of preserving the affected 
valve, a very low postoperative recurrence rate, and a re-
duction in the risk of CPF-related systemic embolism. 
Of course, adequate surgical expertise is a must. Further 
research is needed to evaluate the effectiveness of anti-
platelet or anticoagulation therapy, especially in patients 
who are not candidates for surgical intervention or who 
decline surgical intervention. Due to the possible presence 
of thrombotic mass on the tumor surface, antithrombotic 
therapy should be considered.
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